MEMS-Based Innovations for Optimized Management of Type I Diabetes: 20 April @ 6PM
IEEE CC eVENT – 20 April @ 6PM – Professor Sumita Pennathur Presents:
MEMS-Based Innovations for Optimized Management of Type I Diabetes
Link to Register for EVENT https://events.vtools.ieee.org/event/register/310391
Location – Rusty’s Pizza 5934 Calle Real, Goleta, CA 93117
6:00 PM – Complimentary Pizza, Salad, Beverage
6:25 PM – Central Coast Status
6:30 PM – Professor Pennathur’s Presentation
Please join us at Rusty’s on 20 April 2022 @ 6PM when Professor Pennathur will speak on MEMS (Micro-Electromechanical Systems).
MEMS-based Innovations for Optimized Management of Type I Diabetes
Achievement of good glucose control in patients with diabetes depends on frequent self-monitoring of blood glucose values and appropriate insulin adjustment and administration. Avoiding such control can result in hypo- and hyperglycemia and life-threatening diabetic ketoacidosis. The most advanced control is achieved by the continuous communication between continuous glucose monitors (CGMs) and insulin pumps for closed loop delivery, typically referred to as an artificial pancreas (AP) system. Although AP systems are nascently entering the marketplace, they all require a separate wearable glucose sensor on the body to achieve closed-loop delivery. Furthermore, every commercial pump and sensor to date measure and deliver within the subcutaneous space (~5mm deep). This is known to have a lag compared to sensing and delivery in the dermal space (~1mm deep), limiting the efficiency of existing AP systems. The ultimate vision is to produce a small footprint, easy-to-use artificial pancreas (AP) system (i.e., integrated CGM and insulin pump) using past accomplishments in both microfluidics and microfabrication, as well as her strong motivation due to Pennathur’s recently diagnosed Type 1 diabetic daughter. This includes both the development of microneedle-based CGM systems to sensing glucose in the dermal space as well as innovative pump mechanisms to achieve insulin dosing within the dermal space that meets specifications of size, power, and performance for facile integration with dermal CGM technology into a small-footprint, wearable patch pump-based AP system. Such innovations represent a major step towards revolutionizing the management of diabetes.